Information Provided By:
Fly News Breaks for December 19, 2019
APLS
Dec 19, 2019 | 06:40 EDT
BofA/Merrill analyst Brian Cheng initiated coverage of Apellis Pharmaceuticals with a Buy rating and $36 price target. The analyst expects the company's paroxysmal nocturnal hemoglobinuria in January for APL-2 should validate C3 as a therapeutic target in diseases mediated by complement. He believes the value of the totality of data is being overlooked by investors.
News For APLS From the Last 2 Days
There are no results for your query APLS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.